Abstract
Pharmacological intervention is the commonest mode of managing patients with schizophrenia. Both clinicians and patients are concerned that antipsyohotic drugs are costly and contribute to poor drug compliance in India. This study compared the equivalent doses of antipsychotic drugs and their costs across brands. Results show that antipsychotic drugs are affordable and are comparable to drug treatment costs of other physical illnesses. However, coprescription of drugs add to the burden. Numerous brands and a 2-2-1/2 fold difference in cost raises many concerns including that of drug bioavailability. Hence, the authors recommend consensus and formulation of guidelines for the pharmacological management of schizophrenia.
Keywords: Schizophrenia, drug comparability, cost
Full Text
The Full Text of this article is available as a PDF (176.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davies L. M., Drummond M. F. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry. 1993 Jan;162:38–42. doi: 10.1192/bjp.162.1.38. [DOI] [PubMed] [Google Scholar]
- Lehman A. F., Steinwachs D. M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1–10. doi: 10.1093/oxfordjournals.schbul.a033302. [DOI] [PubMed] [Google Scholar]
- Zito J. M. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am. 1998 Mar;21(1):181–202. doi: 10.1016/s0193-953x(05)70366-x. [DOI] [PubMed] [Google Scholar]